Matinas BioPharma (NYSE:MTNB) CEO & Co-founder Jerry Jabbour joins Natalie Stoberman from the Proactive newsroom to discuss the company's latest growth and momentum surrounding its MAT2203 trial as a potential oral broad-spectrum treatment for invasive deadly fungal infections.
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company is also developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform.